{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T19:47:29Z","timestamp":1767383249578},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["diabetesresearchclinicalpractice.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.diabres.2016.07.012","type":"journal-article","created":{"date-parts":[[2016,7,29]],"date-time":"2016-07-29T11:20:36Z","timestamp":1469791236000},"page":"31-39","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Aspirin for primary prevention of cardiovascular disease in patients with diabetes: A meta-analysis"],"prefix":"10.1016","volume":"120","author":[{"given":"Lianne A.","family":"Kokoska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheila M.","family":"Wilhelm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Candice L.","family":"Garwood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen D.","family":"Berlie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2016.07.012_b0005","unstructured":"Heart disease facts. Centers for Disease Control and Prevention. Atlanta, GA, 2014. Available at http:\/\/www.cdc.gov\/heartdisease\/facts.htm [last accessed May 18, 2016]."},{"key":"10.1016\/j.diabres.2016.07.012_b0010","unstructured":"Stroke facts. Centers for Disease Control and Prevention. Dallas, TX, 2014. Available at http:\/\/www.cdc.gov\/stroke\/facts.htm [last accessed May 18, 2016]."},{"key":"10.1016\/j.diabres.2016.07.012_b0015","series-title":"Cardiovascular disease and diabetes","year":"2012"},{"issue":"Suppl. 1","key":"10.1016\/j.diabres.2016.07.012_b0020","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.2337\/dc09-S013","article-title":"Standards of medical care in diabetes \u2013 2009","volume":"32","author":"American Diabetes Association","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2016.07.012_b0025","unstructured":"American Diabetes Association, Standards of medical care in diabetes \u2013 2015, in diabetes care, 2015: United States."},{"issue":"Suppl. 1","key":"10.1016\/j.diabres.2016.07.012_b0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP.13.S1.1","article-title":"American Association of Clinical Endocrinologists (AACE) medical guidelines for clinical practice for the management of diabetes mellitus","volume":"13","author":"Rodbard","year":"2007","journal-title":"Endocr Pract"},{"issue":"Suppl. 2","key":"10.1016\/j.diabres.2016.07.012_b0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP.17.S2.1","article-title":"American Association of Clinical Endocrinologists (AACE) medical guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan","volume":"17","author":"Handelsman","year":"2011","journal-title":"Endocr Pract"},{"key":"10.1016\/j.diabres.2016.07.012_b0040","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1475-2840-10-25","article-title":"Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis","volume":"10","author":"Butalia","year":"2011","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabres.2016.07.012_b0045","doi-asserted-by":"crossref","first-page":"b4531","DOI":"10.1136\/bmj.b4531","article-title":"Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials","volume":"339","author":"De Berardis","year":"2009","journal-title":"Br Med J"},{"issue":"2","key":"10.1016\/j.diabres.2016.07.012_b0050","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.diabres.2009.09.029","article-title":"Aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis","volume":"87","author":"Zhang","year":"2010","journal-title":"Diabetes Res Clin Pract"},{"issue":"9","key":"10.1016\/j.diabres.2016.07.012_b0055","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1517\/14656561003792538","article-title":"Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a meta-analysis","volume":"11","author":"Younis","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.diabres.2016.07.012_b0060","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.2337\/dc09-1297","article-title":"Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes","volume":"32","author":"Calvin","year":"2009","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.diabres.2016.07.012_b0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MAJ.0b013e3181f1fba8","article-title":"Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis","volume":"341","author":"Stavrakis","year":"2011","journal-title":"Am J Med Sci"},{"issue":"1","key":"10.1016\/j.diabres.2016.07.012_b0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"issue":"7414","key":"10.1016\/j.diabres.2016.07.012_b0075","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"Br Med J"},{"issue":"10","key":"10.1016\/j.diabres.2016.07.012_b0080","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The prisma statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"62","author":"Liberati","year":"2009","journal-title":"J Clin Epidemiol"},{"issue":"10","key":"10.1016\/j.diabres.2016.07.012_b0085","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1001\/jama.1992.03490100090033","article-title":"Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early treatment diabetic retinopathy study report 14","volume":"268","author":"ETDRS Investigators","year":"1992","journal-title":"J Am Med Assoc"},{"issue":"18","key":"10.1016\/j.diabres.2016.07.012_b0090","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1001\/jama.2008.623","article-title":"Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial","volume":"300","author":"Ogawa","year":"2008","journal-title":"J Am Med Assoc"},{"issue":"3","key":"10.1016\/j.diabres.2016.07.012_b0095","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJM198907203210301","article-title":"Final report on the aspirin component of the ongoing Physicians\u2019 Health Study. Steering Committee of the Physicians\u2019 Health Study Research Group","volume":"321","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2016.07.012_b0100","doi-asserted-by":"crossref","first-page":"a1840","DOI":"10.1136\/bmj.a1840","article-title":"The Prevention of Progression of Arterial Disease and Diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease","volume":"337","author":"Belch","year":"2008","journal-title":"Br Med J"},{"issue":"12","key":"10.1016\/j.diabres.2016.07.012_b0105","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.2337\/diacare.26.12.3264","article-title":"Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial","volume":"26","author":"Sacco","year":"2003","journal-title":"Diabetes Care"},{"issue":"13","key":"10.1016\/j.diabres.2016.07.012_b0110","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa050613","article-title":"A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women","volume":"352","author":"Ridker","year":"2005","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.diabres.2016.07.012_b0115","article-title":"Aspirin treatment and risk of first incident cardiovascular diseases in patients with type 2 diabetes: an observational study from the Swedish National Diabetes Register","volume":"3","author":"Ekstrom","year":"2013","journal-title":"Br Med J"},{"issue":"2","key":"10.1016\/j.diabres.2016.07.012_b0120","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2337\/dc09-1701","article-title":"Aspirin is associated with reduced cardiovascular and all-cause mortality in type 2 diabetes in a primary prevention setting: the fremantle diabetes study","volume":"33","author":"Ong","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2016.07.012_b0125","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1475-2840-8-57","article-title":"Lack of benefits for prevention of cardiovascular disease with aspirin therapy in type 2 diabetic patients\u2013a longitudinal observational study","volume":"8","author":"Leung","year":"2009","journal-title":"Cardiovasc Diabetol"},{"issue":"9118","key":"10.1016\/j.diabres.2016.07.012_b0130","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2016.07.012_b0135","doi-asserted-by":"crossref","unstructured":"Ikeda Y, Shimada K, Teramoto T, et al., Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. J Am Med Assoc, 2014. 312(23): p. 2510\u201320.28. ACCEPT-D: Giorgia De Berardis, Michele Sacco, Virgilio Evangelista, Alessandro Filippi, Carlo B Giorda, Gianni Tognoni, Umberto Valentini, Antonio Nicolucci, ACCEPT-D Study Group Trials. 2007; 8: 21. Published online 2007 August 28. doi: 10.1186\/1745-6215-8-21.","DOI":"10.1186\/1745-6215-8-21"},{"issue":"21","key":"10.1016\/j.diabres.2016.07.012_b9005","volume":"8","author":"De Berardis","year":"2007","journal-title":"Trials"},{"key":"10.1016\/j.diabres.2016.07.012_b0140","unstructured":"ASCEND: A study of cardiovascular events iN diabetes. University of Oxford, 2015. Available at https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00135226 [last accessed May 18, 2016]."}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822716302674?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822716302674?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T05:27:06Z","timestamp":1536557226000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822716302674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":29,"alternative-id":["S0168822716302674"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2016.07.012","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aspirin for primary prevention of cardiovascular disease in patients with diabetes: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2016.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}